CORE
Metadata, citation and similar papers at core.ac.uk
Provided by Elsevier - Publisher Connector

Multiplexed Molecular Profiling of Lung Cancer Using Pleural Effusion

Hiroaki Akamatsu, MD,†‡ Yasuhiro Koh, MD, PhD,† Hirotsugu Kenmotsu, MD,* Tateaki Naito, MD, PhD,* Masakuni Serizawa, PhD,† Madoka Kimura, MD,*§ Keita Mori, MSc,‖ Hisao Imai, MD, PhD,* Akira Ono, MD, PhD,*Takehito Shukuya, MD,*¶ Tetsuhiko Taira, MD, PhD,* Haruyasu Murakami, MD, PhD,* Yasuhisa Ohde, MD, PhD,# Masahiro Endo, MD, PhD,** Takashi Nakajima, MD, PhD,†† Toshiaki Takahashi, MD, PhD,* and Nobuyuki Yamamoto, MD, PhD*‡*

Introduction: Pleural effusion is frequently observed in patients with advanced lung cancer. Although effusion can be obtained less invasively and repeatedly, its use in multiplexed molecular profiling has not been fully investigated.

Methods: Between July 2011 and April 2013, pleural effusion samples were obtained from patients with lung cancer at Shizuoka Cancer Center. They were analyzed for *EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN,* and *HER2* mutations, *EGFR, MET, FGFR1, FGFR2,* and *PIK3CA* amplifications, and *ALK, ROS1,* and *RET* fusion genes using pyrosequensing and/or capillary electrophoresis, quantitative reverse-transcriptase polymerase chain reaction, and reverse-transcriptase polymerase chain reaction, respectively.

Results: One hundred and two samples from 84 patients were analyzed. Adenocarcinoma was the most common histological subtype (82%). Genetic abnormalities were detected in 42% of patients. The most common abnormality was *EGFR* mutation (29%), followed by *EML4-ALK* rearrangement (5%), *KRAS* mutation, *and EGFR* amplification (4%, each). Concordance rates between pleural effusion and matched formalin-fixed, paraffin-embedded samples were 88%. Among 11 patients who provided samples at multiple time points, changes in molecular profile over the course of treatment were observed in five patients.

Conclusions: The use of pleural effusion for multiplexed molecular testing and real-time monitoring in lung cancer was demonstrated.

Key Words: Multiplexed molecular testing, Driver mutation, Pleural effusion, Lung cancer

(*J Thorac Oncol.* 2014;9: 1048–1052)

*Division of Thoracic Oncology, Shizuoka Cancer Center, Shimonagakubo; †Division of Drug Discovery and Development, Shizuoka Cancer Center Research Institute, Nagaizumi-cho, Sunto-gun, Shizuoka; ‡Third Department of Internal Medicine, Wakayama Medical University, Kimiidera, Wakayama; §Departments of Thoracic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Higashinari-ku, Osaka; ‖Clinical Trial Management Department, Shizuoka Cancer Center, Shimonagakubo, Nagaizumi-cho Sunto-gun, Shizuoka; ¶Department of Respiratory Medicine, Juntendo University, Tokyo; #Division of Thoracic Surgery; **Division of Diagnostic Radiology; and ††Division of Diagnostic Pathology, Shizuoka Cancer Center, Shimonagakubo, Nagaizumi-cho Sunto-gun, Shizuoka, Japan.

This work was supported by JSPS KAKENHI Grant Numbers 24591186 (N.Y.) and 24501363 (Y.K.).

Disclosure: The authors declare no conflicts of interest.

Address for correspondence: Yasuhiro Koh, MD, Third Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Japan. E-mail: ykoh@wakayama-med.ac.jp

Copyright © 2014 by the International Association for the Study of Lung Cancer

ISSN: 1556-0864/14/0907-1048

Development of molecular cancer therapeutics has brought numerous benefits to patients with driver mutations. Non–small-cell lung cancer (NSCLC) is one of such malignancies with targetable genetic alterations. In NSCLC patients who harbor epidermal growth factor receptor (*EGFR*) mutation, EGFR-tyrosine kinase inhibitors double progression-free survival compared with platinum containing chemotherapy.[1] In 2007, *anaplastic lymphoma kinase (ALK)* rearrangement was discovered in approximately 5% of NSCLC,[2] and ALK inhibitor (crizotinib) was rapidly approved in 5 years, both in the United States and Japan. Today, druggable oncogenes other than *EGFR* and *ALK* have been detected,[3,4] and development of specific inhibitors is underway.

In the era of multiplexed molecular profiling, tumors should be tagged with some genetic abnormalities before treatment. To detect such abnormalities, an ample yield of tumor cells is necessary. Among lung cancer patients, pleural effusion is observed in 7–15%,[5] and it can be obtained less invasively and repeatedly compared with primary lesion. Although pleural effusion is a potential candidate for molecular testing, its use in multiplexed molecular profiling has not been fully investigated.

In July 2011, we started the "Shizuoka lung cancer mutation study," a prospective tumor genotyping study of patients with thoracic malignancies. Using these samples, we conducted a multiplexed molecular profiling of advanced lung cancer with pleural effusion.

MATERIALS AND METHODS

Patient Selection and Samples

Between July 2011 and April 2013, consecutive patients with pathologically confirmed lung cancer at Shizuoka Cancer Center were enrolled in the "Shizuoka

lung cancer mutation study”. Written informed consent was obtained from all participants, and this study was approved by the institutional review board of our hospital. The diagnosis of the tumor was done by institutional pathologists in accordance with the 2004 World Health Organization classification. Pleural effusion samples of up to 250 ml were obtained at the time of diagnosis or therapeutic drainage. To analyze concordance rate of molecular profile between pleural effusion and tissue samples, formalin-fixed, paraffin-embedded (FFPE) samples at the time of diagnosis were provided. Results of mutational testing were communicated to clinicians.

Molecular Analyses of Pleural Effusion and Tissue Samples

Cell isolation from pleural effusion was performed and sored at −80°C until use. Genomic DNAs were extracted using QIAamp DNA mini kit (QIAGEN, Hilden, Germany). From FFPE samples, DNAs were extracted using QIAamp DNA FFPE tissue kit (QAIGEN). DNA concentration was measured using Quant-iT PicoGreen dsDNA assay kit (Invitrogen, Carlsbad, CA). Total RNAs were extracted from pleural effusion with RNeasy Mini kit (QIAGEN) and measured by spectrophotometer (NanoDrop 2000C; Thermo Scientific, Wilmington, DE). They were analyzed for *EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN,* and *HER2* mutations, *EGFR, MET, FGFR1, FGFR2,* and *PIK3CA* amplifications, and *ALK, ROS1,* and *RET* fusion genes using pyrosequensing and/or capillary electrophoresis, quantitative reverse-transcriptase polymerase chain reaction, (qRT-PCR) and RT-PCR, respectively (Tables 1 and 2). Each analyzing method is described in the Supplemental Digital Content 1 (http://links.lww.com/JTO/A601).

TABLE 1. Multiple Tumor Genotyping Panel

Mutations Gene	Position	AA Mutant	Nucleotide Mutant
EGFR	G719	G719C/S	2155G>T/A
		G719A	2156G>C
	exon 19	Deletion	
	T790	T790M	2369C>T
	exon 20	Insertion	
	L858	L858R	2573T>G
	L861	L861Q	2582T>A
KRAS	G12	G12C/S/R	34G>T/A/C
		G12V/A/D	35G>T/C/A
	G13	G13C/S/R	37G>T/A/C
		G13D/A	38G>A/C
	Q61	Q61K	181C>A
		Q61R/L	182A>G/T
		Q61H	183A>T/C
BRAF	G466	G466V	1397G>T
	G469	G469A	1406G>C
	L597	L597V	1789C>G
	V600	V600E	1799T>A
PIK3CA	E542	E542K	1624G>A
	E545	E545K/Q	1633G>A/C
	H1047	H1047R	3140A>G
NRAS	Q61	Q61K	181C>A
		Q61L/R	182A>T/G
MEK1 (MAP2K1)	Q56	Q56P	167A>C
	K57	K57N	171G>T
	D67	D67N	199G>A
AKT1	E17	E17K	49G>A
PTEN	R233	R233*	697C>T
HER2	Exon 20	Insertion	

TABLE 2. Amplifications and Fusion Genes

Gene Amplifications	Fusion Genes
EGFR	EML4-ALK
MET	CD74-ROS1
PIK3CA	SLC34A2-ROS1
FGFR1	KIF5B-RET
FGFR2	CCDC6-RET

Statistical Analysis

The primary purpose of this study was to explore the use of pleural effusion in multiplexed molecular profiling of advanced lung cancer. Detection rate was defined as the proportion of samples with genetic abnormalities. If multiple samples were obtained from the same patient, results for the first sample were adopted. Detection rate between the two groups (pathologically positive or negative) were analyzed using Fisher’s exact test. Concordance rate of molecular profile between pleural effusion samples and matched FFPE samples were also analyzed. Probability values of < 0.05 indicated a statistically significant difference. All the analyses were performed using JMP ver.7 (SAS Institute Inc., Cary, NC).

RESULTS

Patient Characteristics

Among 845 consecutive patients enrolled in the “Shizuoka lung cancer mutation study” during the study period, pleural effusion samples were obtained from 92 patients. Eight patients were ineligible because further investigations indicated that they did not have lung cancer (three non-thoracic malignancies, one incidence each of malignant pleural mesothelioma, invasive thymoma, thymic carcinoma, tracheal carcinoma, and spindle cell sarcoma). Then, 102 samples from 84 patients were analyzed (Fig. 1).

Patient characteristics are summarized in Table 3. Median age was 69 (range 29–85), 69% were male, 63% were current smokers, and the most common histology was adenocarcinoma (82%). Forty-three samples (42%) were obtained at the time of initial diagnosis. In 11 patients (13%), samples were obtained at multiple time points.

Detection of Genetic Abnormalities

Genetic abnormalities were detected in 35 patients (42%; 95% confidence interval: 31–52%). In 80 patients,

Copyright © 2014 by the International Association for the Study of Lung Cancer



FIGURE 1. Flow chart of the patients analyzed in this study.



FIGURE 2. Proportion of samples with genetic abnormalities among whole population (*N* = 84), pathologically positive patients (*N* = 60), and pathologically negative patients (*N* = 17). In four patients, pathological diagnosis was not given.

TABLE 3. Baseline Characteristics

Characteristic	*N* = 84
Age-year	
Median	69
Range	29–85
Sex-no.(%)	
Male	58 (69)
Female	26 (31)
Smoking status	
Never or light smoker	23 (27)
Current smoker	61 (73)
Histology no.(%)	
Adenocarcinoma	69 (82)
Squamous cell carcinoma	8 (10)
Small cell carcinoma	7 (8)

samples were divided into aliquots and reviewed by institutional pathologist. Among 63 samples that were pathologically positive, genetic abnormalities were detected in 30 samples. On the other hand, among 17 samples that were pathologically negative, abnormalities were detected only in three samples. There was a significant difference in detection rate (48% versus 18%, $p = 0.03$, Fig. 2).

The most common abnormality was *EGFR* mutation (24 patients; Fig. 3). Other abnormalities were as follows; *EML4-ALK* rearrangement (four patients), *KRAS mutation,* and *EGFR* amplification (three patients, each), *PIK3CA* mutation, and *MET* amplification (two patients), *BRAF* mutation, *NRAS* mutation, *AKT* mutation, *ROS1* fusion, and *FGFR1* amplification (one patient, each). Seven patients had multiple genetic alterations simultaneously. The concordance rates between pleural effusion and matched FFPE samples were 88%.

Among 11 patients who provided samples at multiple time points, changes in molecular profiles over the course of treatment were observed in five patients (Table 4). Three harbored *EGFR*-sensitive mutations, and two had *ALK* rearrangement in the first analysis. After EGFR-tyrosine kinase inhibitor (TKI) administration, *EGFR*-mutated patients acquired additional mutation (*exon 20 T790M* mutation). Erlotinib was started in one patient (no. 3), but she progressed in 3 weeks. In *ALK* rearranged patients, *ALK* fusion gene disappeared after crizotinib exposure. In one patient (no. 5), *ALK* fusion gene was detected again in third sample. He was treated with another ALK inhibitor, and it shrinked his tumor for 7 months.

DISCUSSION

Sequist et al. reported a multiplexed PCR-based genotyping system for NSCLC.[6] They extracted DNA from FFPE specimens that were prescreened by a pathologist. They demonstrated that half of patients had greater than or equal to one genetic abnormality. However, adequate tissue is difficult to obtain from advanced lung cancer patients. Tissue accrual rates in pivotal studies of NSCLC were only approximately 20%.[7] Thus, cytology samples occupy a substantial position in molecular testing today. Pleural effusion is a potential candidate because it can be obtained less invasively and repeatedly. In *EGFR* mutation testing, several studies have demonstrated the use of pleural effusion.[8,9] In this study, we aimed to get one step further and explored multiplexed molecular profiling using pleural effusion and achieved a comparable detection rate (42%) to Sequist's analysis with FFPE samples.

Our analysis teaches the importance of screening malignant cells by pathologists before genetic testing. However, the 18% detection rate shown in samples without malignant cells should not be considered negligible. Buttitta et al.[11] analyzed effusion samples with few or no malignant cells using direct sequencing and next generation sequencing (NGS).[10] Surprisingly, NGS detected *EGFR* mutation in 42% of samples without malignant cells, whereas direct sequencing could not detect any mutation. Pathologically positive samples contain at least 1% cancer cells, in general. Buttitta et al.'s[11] data suggest that highly sensitive methods may be superior to pathological diagnosis. Clinicians can try molecular profiling even with pathologically negative samples, if highly sensitive methods such as NGS and digital PCR are available.

Copyright © 2014 by the International Association for the Study of Lung Cancer



FIGURE 3. Relative frequency of genetic abnormalities analyzed from 102 pleural effusion samples.

TABLE 4. Details of Five Patients Who Provided Changes in Molecular Profile over the Courses of Treatment

NO.	Clinical Background	Molecular Profile of First Sample	Treatment	Molecular Profile of Second Sample	Clinical Course After Second Sample
1	EGFR-TKI naïve	*EGFR (L858R)*	Erlotinib	*EGFR (L858R + T790M)*	Best supportive care
2	EGFR-TKI naïve	*EGFR (G719S)*	Gefitinib	*EGFR (G719S + T790M)*	Best supportive care
3	EGFR-TKI naïve	*EGFR (exon19del)*	Gefitinib	*EGFR (exon19del + T790M)*	Erlotinib was not effective.
4	ALK-TKI naïve	*EML4-ALK (v3a/3b)*	Crizotinib	Not detected	Crizotinib was not effective.
5	ALK-TKI naïve	*EML4-ALK (v3a/3b)*	Crizotinib	Not detected	*EML4-ALK(v3a/3b)* was detected from third sample, and another ALK-TKI was effective.

Even in a small subset, we demonstrated relatively higher concordance rates (88%) between pleural effusion and FFPE samples. This was comparable with Vignot's report that demonstrated higher concordance rates (94%) using next generation sequencing between primary and matched metastatic samples obtained by surgery in 15 patients.[11]

At last, we could observe changes of molecular profile over the course of treatment in five patients. Such a monitoring strategy of molecular profiling was already attempted in metastatic breast cancer.[12] Among *EGFR*-mutated lung cancer patients, Sequiest et al. reported the mechanism of resistance in detail.[13] *T790M* mutation was the most common (49%), but *MET, EGFR* amplification, *PIK3CA* mutation, and transformation to small cell lung cancer were also observed. To choose subsequent therapy, identifying these molecular changes may provide some help.

Our analysis has some limitations. First of all, our study contained various types of lung cancer. Second, the timing of effusion samples obtainment and their volume depended on investigators' discretion. Therefore, our detection rate of ours should be interpreted cautiously.

In conclusion, this is the first report to investigate the use of pleural effusion using multiplexed molecular testing in lung cancer. Our analysis was able to detect genetic abnormalities in 42% of samples, and concordance rates between pleural effusion and tissue samples were relatively high. In some cases, molecular profiles could be monitored with pleural effusion.

ACKNOWLEDGMENTS

We thank all the patients who participated in this study and their families. We also thank Ms. Mie Yamada (Division of Thoracic Oncology, Shizuoka Cancer Center) for data management; Mr. Masato Abe (Division of Pathology, Shizuoka Cancer Center), Ms. Akane Naruoka, and Ms. Junko Suzuki (Division of Drug Discovery and Development, Shizuoka Cancer Center Research Institute) for sample preparation and analysis, Dr. Tomohiro Maniwa, Dr. Shoji Takahashi, Dr. Masashi Nagata, Dr. Yoshikane Yamauchi, Dr. Naoko Miyata, Dr. Hideaki Kojima, Dr. Yoshiki Kozu, Dr. Chihiro Yamatani, Dr. Kazuo Nakagawa, and Dr. Haruhiko Kondo (Division of Thoracic Surgery); and Dr. Kazushige Wakuda, Dr. Takuya Oyakawa, Dr. Yasushi Hisamatsu, Dr. Ryo Ko, Dr. Shota Omori, Dr. Kazuhisa Nakashima, Dr. Yukiko Nakamura, Dr. Asuka Tsuya, Dr. Takaaki Tokito, Dr. Hirofumi Eida, and Dr. Chikara Sakaguchi (Division of Thoracic Oncology, Shizuoka Cancer Center) for their contributions to this study.

Copyright © 2014 by the International Association for the Study of Lung Cancer

REFERENCES

1. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010;362:2380–2388.
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007;448:561–566.
3. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol* 2012;30:863–870.
4. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. *Nat Med* 2012;18:375–377.
5. Pass HI, Carbone DP, Johnson DH, et al. *Principles and Practice of Lung Cancer*. Fourth edition. Lippincott Williams and Wilkins; 2010.
6. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. *Ann Oncol* 2011;22:2616–2624.
7. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. *Nat Rev Cancer* 2010;10:760–774.
8. Goto K, Satouchi M, Ishii G, et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. *Ann Oncol* 2012;23:2914–2919.
9. Yeo CD, Kim JW, Kim KH, et al. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing. *Lung Cancer* 2013;81:207–212.
10. Buttitta F, Felicioni L, Del Grammastro M, et al. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. *Clin Cancer Res* 2013;19:691–698.
11. Vignot S, Frampton GM, Soria JC, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. *J Clin Oncol* 2013;31:2167–2172.
12. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. *N Engl J Med* 2013;368:1199–1209.
13. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 2011;3:75ra26.

Copyright © 2014 by the International Association for the Study of Lung Cancer